General Info

Novelos Therapeutics is a biotechnology company that develops and markets oxidized glutathione-based compounds for the treatment of cancer and hepatitis. Its developmental drug, NOV-002, is designed to treat chemotherapy-resistant ovarian cancer and acute radiation injury. NOV-002, a second compound, is designed to act as a hepatoprotective agent with immunomodulating and antiviral activity. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation, where they were originally developed. Novelos has corporate headquarters in Newton, Mass., and trades on the Over The Counter Bulletin Board under the symbol NVLT.